Sheep Pox Vaccine Section
The Sheep Pox Vaccine Section is responsible for the development and production of live attenuated vaccines for controlling Sheep Pox and Goat Pox diseases in small ruminants. This section contributes significantly to livestock health, rural livelihoods, and national disease eradication programs through the consistent supply of safe and effective vaccines.
Overview
The Sheep Pox Vaccine Section produces vaccines against Sheep Pox and Goat Pox, both caused by Capripoxvirus infections. The vaccines developed here are live attenuated formulations offering broad and durable immunity across flocks under field conditions.
This section’s operations adhere to Good Manufacturing Practices (GMP) and biosafety standards for viral vaccine production, ensuring consistency and compliance.
Vaccine Specifications
- Type: Live attenuated vaccine using Sheep Pox Virus (SPPV) strain
- Dosage: 0.5 ml for sheep and goats
- Route: Subcutaneous injection
- Onset of Immunity: Within 14 days after vaccination
- Duration: Provides protection for up to one year
- Presentation: 50-dose and 100-dose lyophilized vials
Infrastructure and Facilities
The Sheep Pox Vaccine Section operates with biosecure production and testing infrastructure, including:
- • BSL-2 compliant virology laboratories
- • Embryonated egg inoculation and virus propagation units
- • Controlled environment clean rooms
- • Lyophilization and cold storage systems
- • Quality control and animal testing facilities
Research and Development
The R&D team focuses on strain improvement, thermostable vaccine formulations, and combined vaccine trials for integrated disease prevention in small ruminants. Collaborative studies with veterinary research institutes enhance product innovation.
Quality Assurance
Each vaccine batch undergoes stringent testing for sterility, potency, and safety before release. The section complies with national and OIE guidelines for veterinary biologicals to ensure consistent protection in the field.